LCTX

#3094
Lineage Cell Therapeutics, Inc.
1.6350 USD
+2.83%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.6200
1.6650
Jahresspanne
1.4200
1.9850
Tagesänderung
+2.83%
Monatliche Änderung
+4.14%
6 month change
-4.78%
Jahresänderung
-4.78%
Vorheriger Schlusskurs
1.5900
Eröffnung
1.6650
Bid
Ask
Tief
1.6200
High
1.6650
Volumen
560
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 407.2581 M
  • Employee 77
  • Founded 1990
  • CEO N/A
  • Website www.lineagecell.com
  • Headquarter California, United States
  • FIGI BBG000G8RJY6
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-5.96
Preis-Umsatz-Verhältnis
26.4

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

Nachrichten